Latest news with #NuvationBioInc
Yahoo
12-05-2025
- Business
- Yahoo
Nuvation Bio to Participate in Upcoming Investor Conferences
NEW YORK, May 12, 2025--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats at three upcoming investor conferences: H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025, at 3:00 p.m. ET in New York, NY 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 1:35 p.m. ET in New York, NY TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 28, 2025, at 3:30 p.m. ET (virtual) Live webcasts of each presentation will be available on the Nuvation Bio website at An archived recording will be available for 90 days following each event. About Nuvation Bio Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment by developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib, a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; NUV-1511, an innovative drug-drug conjugate (DDC) designed for targeted cancer treatment; and NUV-868, a BD2-selective BET inhibitor. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit or follow the company on LinkedIn and X (@nuvationbioinc). View source version on Contacts Nuvation Bio Investor Contact: ir@ Nuvation Bio Media Contact: media@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
22-04-2025
- Business
- Business Wire
Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial results beginning at 4:30 p.m. ET. The U.S. Food and Drug Administration assigned taletrectinib's New Drug Application with a Prescription Drug User Fee Act goal date of June 23, 2025. Investors and the general public are invited to listen to a live webcast of the call at Materials related to the call will be available prior to the start of the conference call. A replay of the webcast will be available after the conference call concludes. About Nuvation Bio Nuvation Bio is a global oncology company focused on solving some of the toughest challenges in cancer treatment by developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib, a third-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; NUV-1511, an innovative drug-drug conjugate (DDC) designed for targeted cancer treatment; and NUV-868, a BD2-selective BET inhibitor. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit or follow the company on LinkedIn and X (@nuvationbioinc).
Yahoo
16-04-2025
- Business
- Yahoo
Is Nuvation Bio Inc. (NYSE:NUVB) the Best Biotech Penny Stock to Buy According to Hedge Funds?
We recently published a list of the . In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against other biotech penny stocks. Peter Marks's departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas. First the vaccine approvals and the subsequent resurgence of new vaccines over the past two decades, and then the establishment of the cell and gene therapy field that he's credited for. He was involved in developing policies aimed at optimizing the process of bringing several innovative products to the market. Following his resignation, a substantial number of other departures are also anticipated, which implies upcoming destabilization at the FDA for its existing expertise and processes. Stifel head of biotech research Paul Matteis suggests looking for biotech names not dependent on the FDA while this sector uncertainty lasts. On March 31, Paul Matteis appeared on CNBC's 'The Exchange' and noted that biotech investors, particularly those who are focused on developmental-stage companies, are now facing risk. These include scientific, clinical trials, commercial, patent, competition, and regulatory risks. Hence, investors now need to be more selective about their stock selections. Previously, the FDA has been a stabilizing force for the biotech sector and is known for accelerating approvals in areas such as rare diseases and biomarkers. But recent developments have introduced unpredictability. Matteis highlighted that there could be short-term delays in drug approvals due to personnel changes at the FDA, such as the recent departure of the head of the Center for Drug Evaluation and Research (CEDAR). Investors may even need to reevaluate agreements between companies and the FDA regarding drug approvals. While this doesn't make biotech investments completely unsustainable, it does shift the focus toward companies with more predictable growth prospects. This could point to specifically commercial-stage firms or those less reliant on FDA consistency. Talking about vaccine stocks particularly, Matteis pointed out that as much as Peter Marks influenced vaccine-related decisions, he also impacted broader areas like gene therapies and oncology. He fostered innovation through programs like breakthrough therapy designations and initiatives that were aimed at streamlining approvals. Investors are now gravitating toward companies with de-risked profiles that are less dependent on FDA flexibility. Matteis noted that the companies relatively outperforming right now are those that have their success tied to commercial launches rather than regulatory decisions. We sifted through ETFs, stock screeners, and financial media reports to compile a list of the top biotech penny stocks that were trading below $5 as of April 14. We then selected the 13 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2024. The hedge fund data was sourced from Insider Monkey's database which tracks the moves of over 1000 elite money managers. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A close-up of researchers, carefully studying a biopharmaceutical compound in a laboratory. Share Price as of April 14: $1.99 Number of Hedge Fund Holders: 34 Nuvation Bio Inc. (NYSE:NUVB) focuses on unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its lead product candidate is taletrectinib, which is a ROS1 inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer. It also offers Safusidenib, NUV-1511, and NUV-868. The company's lead program remains taletrectinib, which is a next-generation ROS1 inhibitor for advanced ROS1+ non-small cell lung cancer (NSCLC). The FDA granted Priority Review to its NDA with a PDUFA goal date of 23 June 2025, which indicates a potential US launch in mid-2025. Taletrectinib is already approved in China and is being commercialized by Innovent Biologics. A Marketing Authorization Application (MAA) has been submitted in Japan by Nippon Kayaku as well. Nuvation Bio Inc. (NYSE:NUVB) also launched a US Expanded Access Program (EAP) in February 2025 for eligible patients. The upcoming FDA decision on taletrectinib will be a key milestone and will unlock funding and establish taletrectinib as Nuvation Bio's first commercial product in the US. As of 31 December 2024, the company held $502.7 million in cash and marketable securities. Overall, NUVB ranks 5th on our list of the best biotech penny stocks to buy according to hedge funds. While we acknowledge the growth potential of NUVB, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NUVB but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
09-04-2025
- Business
- Yahoo
Nuvation Bio Inc. (NUVB): Among Stocks Under $10 that Will Triple
We recently published a list of . In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the U.S. small-cap stocks, which are struggling amid broader market challenges due to ongoing shifts in tariff policy, affecting investors' confidence. The Russell index (which tracks small-cap stocks) has fallen over 15% from its peak in November 2024 as of the time of writing this article and is down by nearly 19% on a YTD basis. However, the broader market, mostly consisting of large-cap stocks, has only dropped about 14% on a YTD basis. This gap shows how economic uncertainties and higher interest rates have more impact on smaller companies as they typically carry more debt and feel borrowing costs more acutely. Furthermore, trade tensions have added to small-cap stocks' volatility. Reuters reported that Trump's new 25% tariffs on Canadian, Mexican, and Chinese imports rolled out on March 4, with more duties to be imposed by April 2. This measure affects nearly $2.2 trillion in trade and has sparked retaliatory tariffs from Canada and China, which have stoked inflation fears and triggered global market drops. As such, small-cap companies with international supply chains now face higher costs that could damage their profitability. Yet, small-cap stocks might bounce back as Trump's domestic economic growth agenda could benefit these U.S.-based companies. In addition, onshoring and increased capital expenditures (CAPEX) might boost the sector's earnings. Furthermore, analysts believe that stabilizing inflation and easing interest rates could help small-caps recover in the second half of 2025. As such, inflation seems to be leveling off, which is beneficial for small-cap companies. While high rates have pressured these debt-reliant companies, the Federal Reserve's decision to slow rate hikes in late 2024 provided some breathing room. With inflation settling between 1% and 3%—historically complimentary for small-caps—the sector's performance is expected to get a boost. Therefore, as financial market trends are settling, analysts expect small-cap earnings to outpace large-cap in 2025, especially later in the year. A significant move that could be helpful for small-cap stocks is the recovery in mergers and acquisitions (M&A) and initial public offerings (IPOs). Even though deal activity slowed during recession fears, M&A rebounded in 2024 and is expected to continue in 2025. Historically, rising M&A activity has boosted returns across market caps and proven to be beneficial for small-caps, as it makes those companies acquisition targets, increasing investors' interest. Moreover, industry changes and technological advances offer more opportunities to small-cap companies. While the AI boom has mostly helped mega-cap tech industries, many smaller companies are crucial to AI infrastructure in terms of cybersecurity and thermal management. A 2023 PwC report valued the healthcare AI market at $11 billion, projecting its growth to $188 billion by 2030. Despite the market challenges, some small-caps under $10 have beaten the broader market, showing resilience amid inflation and trade uncertainties. They show remarkable growth possibilities even as conditions fluctuate. We chose consensus picks of credible websites and compiled a list of stocks priced at $10 or less that are expected to triple. Furthermore, we used a screener to identify stocks with a projected upside potential of over 300%. We have also assessed the hedge fund sentiment from Insider Monkey's database of over 1,000 elite hedge funds tracked as of the end of the fourth quarter of 2024. The list is arranged in ascending order of the number of hedge fund holders in each stock. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A close-up of researchers, carefully studying a biopharmaceutical compound in a laboratory. Nuvation Bio Inc. (NYSE:NUVB), a clinical-stage biopharma company, develops innovative cancer treatments. The company's lead drug, a ROS1 inhibitor taletrectinib, targets ROS1-positive lung cancer. Simultaneously, Nuvation is also extending its portfolio with safusidenib, which is a targeted inhibitor for brain tumors with IDH1 mutations, and NUV-1511, a drug-drug conjugate for advanced solid tumors. Nuvation Bio Inc. (NYSE:NUVB) ensured robust financial health with $502.7 million in cash, cash equivalents, and marketable securities as of December 31, 2024. R&D spending hit $29.3 million in Q4 2024, reflecting a cost increase from the acquisition of AnHeart Therapeutics and ongoing clinical trials. On the other hand, selling, general, and administrative expenses rose to $26.1 million due to integration efforts and commercialization preparations, resulting in a net quarterly loss of $49.4 million or $0.15 per share. Despite the troubled profitability, Nuvation Bio Inc. (NYSE:NUVB) turned a major cornerstone when the FDA granted a Priority Review to its New Drug Application (NDA) for taletrectinib, with a PDUFA goal date set for June 23, 2025. The drug already got regulatory approval in China, with sales handled by Innovent Biologics. In addition, the company also submitted a Marketing Authorization Application (MAA) in Japan. In the U.S., the company launched an Expanded Access Program for taletrectinib so that eligible patients can receive the drug before commercialization. With substantial cash reserves and access to $250 million in non-dilutive financing from Sagard Healthcare Partners, Nuvation Bio Inc. (NYSE:NUVB) has the cash reserves to commercialize its drugs and develop new ones. As taletrectinib enters the U.S. market and the company's cancer pipeline grows, it is positioned as one of the stocks under $10 that will triple. The company has a high potential for growth once it gets regulatory approval and successful commercialization of its drugs. Overall, NUVB ranks 6th on our list of stocks under $10 that will triple. While we acknowledge the potential of NUVB, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NUVB but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Associated Press
25-03-2025
- Business
- Associated Press
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025
NEW YORK--(BUSINESS WIRE)--Mar 25, 2025-- Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be reported in a mini oral presentation at the European Lung Cancer Congress taking place March 26–29, 2025 in Paris, France. Mini Oral Presentation Overview: Title: Taletrectinib vs crizotinib in ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison Presenter: Misako Nagasaka, M.D., Ph.D., Associate Professor – Division of Hematology and Oncology, UCI School of Medicine Date: Thursday, March 27, 2025 Session Time: 4:00 p.m. – 5:05 p.m. CET / 11:00 a.m. – 12:05 p.m. ET Session: Mini Oral Session 1 Presentation Number: LBA2 The materials will be made available in the Publications section of Nuvation Bio's website after the presentation. About Taletrectinib Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib is being evaluated for the treatment of patients with advanced ROS1+ NSCLC in two Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in China, and TRUST-II (NCT04919811), a global study. Based on pooled results of the TRUST-I and TRUST-II clinical studies, the U.S. FDA has accepted and granted Priority Review to Nuvation Bio's NDA for taletrectinib for advanced ROS1+ NSCLC (line agnostic, full approval) and assigned a PDUFA goal date of June 23, 2025. The U.S. FDA previously granted taletrectinib Breakthrough Therapy Designation for the treatment of patients with locally advanced or metastatic ROS1+ NSCLC who either have or have not previously been treated with ROS1 TKIs, and Orphan Drug Designation for the treatment of patients with ROS1+ NSCLC and other NSCLC indications. In January 2025, China's NMPA approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. About Nuvation Bio Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. Nuvation Bio's programs include taletrectinib (ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, please visit or follow the Company on LinkedIn and X (@nuvationbioinc). INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH HEALTH PHARMACEUTICAL ONCOLOGY SOURCE: Nuvation Bio Inc. Copyright Business Wire 2025. PUB: 03/25/2025 08:00 AM/DISC: 03/25/2025 08:00 AM
